Lead-Likeness and Drug-Likeness

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 244-254

  Polinsky, Alex ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952793240     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00012-3     Document Type: Chapter

References (59)

1. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23:3-25.
2. Hann M.M., Leach A.R., Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inform. Comput. Sci. 2001, 41:856-864.
3. Matter H., Baringhaus K.H., Naumann T., Klabunde T., Pirard B. Computational approaches towards the rational design of drug-like compound libraries. Combin. Chem. High Throughput Screening 2001, 4:453-475.
4. Walters W.P.Ajay, Murcko M.A. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 1999, 3:384-387.
5. Muegge I. Selection criteria for drug-like compounds. Med. Res. Rev. 2003, 23:302-321.
6. Ashby J. Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. Environ. Mutagen. 1985, 7:919-921.
7. World Drug Index, Derwent Information: Alexandria, VA . http://www.derwent.com.
8. Bhal S.K., Kassam K., Peirson I.G., Pearl G.M. The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. Mol. Pharm. 2007, 4:556-560.
9. Ghose A.K., Viswanadhan V.N., Wendoloski J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of know drug databases. J. Combin. Chem. 1999, 1:55-68.
10. Comprehensive Medicinal Chemistry Database, 94.1; Distributed by MDL Information Systems: San Leandro, CA.
11. Oprea T.I. Property distribution of drug-related chemical databases. J. Comput.-Aided Mol. Des. 2000, 14:251-264.
12. Palm K., Stenberg P., Luthman K., Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharmacol. Res. 1997, 14:568-571.
13. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 1999, 88:807-814.
14. Kelder J., Grootenhuis P.D.J., Bayada D.M., Delbressine L.P.C., Ploemen J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharmacol. Res. 1999, 16:1514-1519.
15. Ertl P., Rohde B., Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43:3714-3717.
16. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45:2615-2623.
17. Muegge I., Heald S.L., Brittelli D. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 2001, 44:1841-1846.
18. MACCS-II Drug Data Report Database, Distributed by MDL Information Systems, Inc., San Leandro, CA.
19. Wang J., Ramnarayan K. Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. J. Combin. Chem. 1999, 1:524-533.
20. Xu J., Stevenson J. Drug-like index: a new approach to measure drug-like compounds and their diversity. J. Chem. Inform. Comput. Sci. 2000, 40:1177-1187.
21. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., Lotti V.J., Cerino D.J., Chem T.B., Kling P.J., Kunkel K.A., Springer J.P., Hirshfield J. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31:2235-2246.
22. Mason J.S., Morize I., Menard P.R., Cheney D.L., Hulme C., Labaudiniere R.F. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem. 1999, 42:3251-3264.
23. Nicolaou K.C., Pfefferkorn J.A., Roecker A.J., Cao G.Q., Barluenga S., Mitchell H.J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J. Am. Chem. Soc. 2000, 122:9939-9953.
24. DeSimone R.W., Currie K.S., Mitchell S.A., Darrow J.W., Pippin D.A. Privileged structures: applications in drug discovery. Combin. Chem. High Throughput Screening 2004, 7:473-493.
25. PHARMABlock® Proprietary Combinatorial Building Blocks, ChemBridge Corporation: San Diego, CA, . http://www.chembridge.com.
26. Optimer Building Blocks, Array Biopharma: Bolder, CO, . http://www.arraybiopharma.comwww.arraybiopharma.com.
27. Bemis G.W., Murcko M.A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39:2887-2893.
28. Bemis G.W., Murcko M.A. Properties of known drugs. 2. Side chains. J. Med. Chem. 1999, 42:5095-5099.
29. WOMBAT 2006.1, Distributed by Sunset Molecular Discovery LLC: Santa Fe, NM.
30. The PubChem Database, Available online at the National Center for Biotechnology Information, . http://pubchem.ncbi.nlm.nih.gov/.
31. Walters W.P.Ajay, Murcko M.A. Can we learn to distinguish between drug-like and nondrug-like molecules?. J. Med. Chem. 1998, 41:3314-3324.
32. Sadowski J., Kubinyi H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41:3325-3329.
33. Frimurer T.M., Bywater R., Naerum L., Lauritsen L., Brunak S. Improving the odds in discriminating drug-like from non drug-like compounds. J. Chem. Inform. Comput. Sci. 2000, 40:1315-1324.
34. Gillet V.J., Willett P., Bradshaw J. Identification of biological activity profiles using substructural analysis and genetic algorithms. J. Chem. Inform. Comput. Sci. 1998, 38:165-179.
35. Wagener M., van Geerestein V.J. Potential drugs and nondrugs: prediction and identification of important structural features. J. Chem. Inform. Comput. Sci. 2000, 40:280-292.
36. Muller K.R., Ratsch G., Sonnenburg S., Mika S., Grimm M., Heinrich N. Classifying 'drug-likeness' with kernel-based learning methods. J. Chem. Inform. Model 2005, 45:249-253.
37. Jorgensen W.L., Duffy E.M. Prediction of drug solubility from Monte Carlo simulations. Bioorg. Med. Chem. Lett. 2000, 10:1155-1158.
38. QikProp, Schrodinger, Inc., Portland, OR. http://www.schrodinger.com.
39. Balakin K.V., Savchuk N.P., Tetko I.V. In Silico approaches to prediction of aqueous and DMSO solubility of drug-like compounds: trends, problems and solutions. Curr. Med. Chem. 2006, 13:223-241.
40. Hou T., Wang J., Zhang W., Wang W., Xu X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr. Med. Chem. 2006, 13:2653-2667.
41. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 1999, 88:815-821.
42. Ecker G.F., N.C.R. In Silico prediction models for blood-brain barrier permeation. Curr. Med. Chem. 2004, 11:1617-1628.
43. MetabolExpert, CompuDrug: South San Francisco, CA. http://www.compudrug.com.
44. META, Charles River Laboratories: Wilmington, MA. http://www.criver.com.
45. Yang C., Benz R.D., Cheeseman M.A. Landscape of current toxicity databases and database standards. Curr. Opin. Drug. Discov. Dev. 2006, 9:124-133.
46. Mohan C.G., Gandhi T., Garg D., Shinde R. Computer-assisted methods in chemical toxicity prediction. Mini-Rev. Med. Chem. 2007, 7:499-507.
47. Richard A.M. Future of toxicology-predictive toxicology: an expanded view of chemical toxicity. Chem. Res. Toxicol. 2006, 19:1257-1262.
48. Proudfoot J.R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 2002, 12:1647-1650.
49. Teague S.J., Davis A.M., Leeson P.D., Oprea T. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. 1999, 38:3743-3748.
50. Oprea T.I., Allu T.K., Fara D.C., Rad R.F., Ostopovichi L., Bologa C.G. Lead-like, drug-like or pub-like: How different are they?. J. Comput.-Aided Mol. Des. 2007, 21:113-119.
51. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA 1999, 96:9997-10002.
52. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 2004, 9:430-431.
53. Leach A.R., Hann M.M., Burrows J.N., Griffen E.J. Fragment screening: an introduction. Mol. BioSyst. 2006, 2:429-446.
54. Congreve M., Carr R., Murray C.W., Jhoti H. A Rule of Three for fragment-based lead discovery?. Drug Discov. Today 2003, 8:876-877.
55. Bohacek R.S., Martin C., Guida W.C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 1996, 16:3-50.
56. Hann M.M., Oprea T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 2004, 8:255-263.
57. Rishton G.M. Reactive compounds and in vitro false positives in HTS. Drug Discov. Today 1997, 2:382-384.
58. Rishton G.M. Non-leadlikeness and leadlikeness in biochemical screening. Drug Discov. Today 2003, 8:86-96.
59. Roche O., Schneider P., Zuegge J., Guba W., Kansy M., Alanine A., Bleicher K., Danel F., Gutknecht E.M., Rogers-Evans M., Neidhart W., Stalder H., Dillon M., Sjogren E., Fotouhi N., Gillespie P., Goodnow R., Harris W., Jones P., Taniguchi M., Tsujii S., von der Saal W., Zimmermann G., Schneider G. Development of a virtual screening method for identification of frequent hitters in compound libraries. J. Med. Chem. 2002, 45:137-142.